CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 11,112 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $12.28, for a total value of $136,455.36. Following the completion of the transaction, the chief technology officer directly owned 167,704 shares in the company, valued at $2,059,405.12. This trade represents a 6.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Raymond Woo also recently made the following trade(s):

• On Tuesday, November 11th, Raymond Woo sold 11,112 shares of CeriBell stock. The stock was sold at an average price of $12.28, for a total transaction of $136,455.36.
• On Friday, October 3rd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $12.54, for a total transaction of $139,344.48.

CeriBell Stock Performance

CBLL opened at $18.00 on Thursday. The company has a 50 day simple moving average of $13.12 and a two-hundred day simple moving average of $14.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. The firm has a market cap of $667.80 million, a P/E ratio of -11.92 and a beta of 1.35. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $32.75.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. Equities analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. TD Cowen dropped their price target on CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Raymond James Financial assumed coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective for the company. Finally, JPMorgan Chase & Co. lowered their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $25.17.

Institutional Trading of CeriBell

A number of large investors have recently added to or reduced their stakes in CBLL. Deutsche Bank AG raised its holdings in shares of CeriBell by 0.4% during the 1st quarter. Deutsche Bank AG now owns 231,629 shares of the company’s stock worth $4,450,000 after acquiring an additional 842 shares in the last quarter. CenterBook Partners LP purchased a new stake in CeriBell during the first quarter valued at $3,531,000. Swiss National Bank bought a new position in CeriBell during the first quarter valued at $467,000. Nuveen LLC purchased a new position in shares of CeriBell in the 1st quarter worth $311,000. Finally, Lord Abbett & CO. LLC increased its holdings in shares of CeriBell by 7.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company’s stock worth $6,138,000 after buying an additional 23,451 shares during the last quarter.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.